Psychedelics As Therapeutic Treatments Focus Of New UW-Madison Psychedelics Master’s Degree

"We're particularly interested in training students to enter the growth pharmaceutical industry surrounding the use of these substances, providing them with the tools to understand the data and also to work in an ethical manner and adhere to all the regulatory pieces surrounding the use of these compounds," he said.

Compass Pathways (CMPS) Potential Lead in Psychedelic Sector

A couple of companies in the Magic Mushroom sector that are worth talking about are Compass Pathways (CMPS) and Minerco, Inc. (MINE). CMPS is ahead in the race is already working on a formulation of psilocybin to help with treatment-resistant depression.

By |2021-04-03T16:55:49-08:00April 3, 2021|Articles & News, Cannabis, Magic Mushrooms|0 Comments

Report Finds People Use Psychedelic Drugs to Self-Medicate for Depression, Anxiety and Trauma

The most common supervisor was a friend or partner, followed by a shamen (a spiritual practitioner), a therapist or counsellor and a family member. The most commonly used substances taken under supervision were LSD, magic mushrooms and ayahuasca.

The Psilocybin Patent Race Is On

Earlier this week, NeonMind (NMDBF) filed for four provisional patents. Psilocybin Alpha said, "The provisional patent applications include data derived from NeonMind's initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss.

By |2021-03-07T12:51:17-08:00March 7, 2021|Articles & News, Magic Mushrooms|0 Comments

Field Trip Health’s New Psilocybin Research Facility Probes the Secrets of Shrooms

“Clinical studies on psilocybin and other plant-based psychedelic compounds have shown that they have great potential to produce profoundly positive changes in individuals, particularly those struggling from serious mental health conditions like anorexia, depression, and PTSD,”

By |2021-02-28T22:21:33-08:00February 28, 2021|Magic Mushrooms, Studies|0 Comments

The Next Revolution in Antidepressants Is Here – LSD, Psilocybin, MDMA, Ketamine & DMT

Psychedelic drugs essentially work opposite of an SSRI. While an SSRI inhibits serotonin processing in the brain to keep a more steady supply, psychedelics flood the brain’s neurotransmitters with chemical compounds present in the drugs that are similar to serotonin.

By |2021-02-28T20:38:41-08:00February 28, 2021|DMT, Ketamine, LSD, Magic Mushrooms, MDMA, Microdosing|0 Comments

Forget Cannabis – Psilocybin May be the Next Big Opportunity

Psygen is a Calgary-based company specializing in the synthetic manufacture of psychedelic medicines. The company provides non-exclusive access to psychedelic drug products for clinical research, therapeutic applications and is a leading supplier for the emerging commercial market.

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica; Hires Leading Psychiatrist as Medical Director

Title

Go to Top